TETERBORO, N.J., Mar 25, 2003 /PRNewswire-FirstCall via COMTEX/ -- Quest
Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of
diagnostic testing, information and services, today announced that Robert E.
Peters has been appointed Vice President, Sales and Marketing.
Mr. Peters will be responsible for leading Sales and Marketing initiatives
driving overall profitable growth through ensuring a comprehensive focus on
meeting the needs of customers.
In 2002, Mr. Peters was named Regional Vice President, East Region. Previously,
he led the company's New York / New Jersey operations.
Prior to joining Quest Diagnostics in 1997, Mr. Peters held a variety of sales
leadership and general management positions at Ciba-Geigy AG (now part of
Novartis) during a period spanning more than twenty years. He eventually held
the position of Vice President, U.S. Operations for the Pharmaceutical Business.
Mr. Peters holds a B.S. Degree from North Carolina State University and an MBA
from Wake Forest University.
Quest Diagnostics Incorporated is the nation's leading provider of diagnostic
testing, information and services, providing insights that enable healthcare
professionals to make decisions that improve health. The company offers the
broadest access to diagnostic testing services in the United States through its
national network of laboratories and patient service centers, and provides
interpretive consultation through its extensive medical and scientific staff.
Quest Diagnostics is the leading provider of esoteric testing, including
gene-based medical testing, and also empowers healthcare organizations and
clinicians with state-of-the-art connectivity solutions that improve patient
care. Additional company information is available at: www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking statements
involve risks and uncertainties that could cause actual results and outcomes to
be materially different. Certain of these risks and uncertainties may include,
but are not limited to, unanticipated expenditures, changing relationships with
customers, suppliers and strategic partners, conditions of the economy and other
factors described in the Quest Diagnostics Incorporated 2002 Form 10-K and
subsequent filings.
SOURCE Quest Diagnostics Incorporated
CONTACT:
Investors - Laure Park, +1-201-393-5030, or Media - Gary
Samuels, +1-201-393-5700, both of Quest Diagnostics Incorporated
URL: http://www.questdiagnostics.com
Copyright (C) 2003 PR Newswire. All rights reserved.